Back to Companies Directory
VERIFIED COMPANY DOSSIER

Neuphoria Therapeutics Inc

Verified Intel

At Neuphoria Therapeutics, we are dedicated to pioneering breakthrough therapies that address the complex needs of individuals affected by neuropsychiatric disorders. By focusing on novel approaches and advancing scientific understanding, we aim to deliver medicines that offer lasting relief and hope for a brighter, healthier future. To learn more about the company, pipeline and collaboration opportunities, visit us at www.neuphoriatx.com 

At Neuphoria Therapeutics, we are dedicated to pioneering breakthrough therapies that address the complex needs of individuals affected by neuropsychiatric disorders. By focusing on novel approaches and advancing scientific understanding, we aim to deliver medicines that offer lasting relief and hope for a brighter, healthier future. To learn more about the company, pipeline and collaboration opportunities, visit us at www.neuphoriatx.com 

Primary SectorGeneral Industry
Workforce Size11-50 Employees
Global HQAdelaide, Australia
Total Capital RaisedBootstrapped / Private

Corporate Firmographics

Entity classification and operating profile

Industry
General
Company Type
Public Company
Founded
Undisclosed
Employee Bracket
11-50
Estimated Revenue Range
Undisclosed

Geographic Coordinates

Headquarters address and regional territory

Street Address
100 Summit Dr Massachusetts Burlington
City
Adelaide
Region / State
South Australia
Postal Code
01803
Country
Australia

Digital Presence & Footprint

Verified domains, socials, and directory profiles

Official Domainneuphoriatx.com
Visit Site
LinkedIn NetworkActive Profile
Open LinkedIn
OUTREACH AUTOMATION

Target Decision-Makers at Neuphoria Therapeutics Inc

Connect your mailboxes, set up your autonomous SDR Agent, and start generating hyper-personalized pipeline for accounts like Neuphoria Therapeutics Inc in minutes.

SYNTHESIZED INTEL

Frequently Asked Questions

Verified business inquiries and firmographic telemetry for Neuphoria Therapeutics Inc.